MB Canno Biosciences Finance - revenue, profit
EBITDA margin (%)
Register and
explore Okredo dataEBIT margin (%)
Register and
explore Okredo dataFinancial statetment report
Price: €9.90
Premium users: 1.00 credit
Premium users: 1.00 credit
Indicator |
---|
Turnover (€) |
Sales per employee (€) |
Profit before tax (€) |
Net Profit (€) |
Profit per employee (€) |
Working capital requirement |
Debt-to-equity ratio |
Total profitability (%) |
Net profitability (%) |
Equity (€) |
Amounts Payable And Liabilities (€) |
Non-current Assets (€) |
CurrentAssets (€) |
EBITDA margin (%) |
EBITDA (€) |
EBIT margin (%) |
EBIT (€) |
2022 |
---|
2,335 |
- |
90 |
90 |
- |
1.27 |
0.00 |
91.09 |
3.85 |
2,975 |
0 |
0 |
2,975 |
2023 |
---|
4,283 |
- |
-1,385 |
-1,385 |
- |
0.77 |
0.06 |
73.38 |
-32.34 |
3,318 |
200 |
0 |
3,518 |
2024 |
---|
1,070 |
- |
759 |
759 |
- |
3.81 |
0.00 |
81.87 |
70.93 |
4,077 |
0 |
0 |
4,077 |
Register and
explore Okredo data2024 |
---|
1,070 |
- |
759 |
759 |
- |
3.81 |
0.00 |
81.87 |
70.93 |
4,077 |
0 |
0 |
4,077 |
Register and
explore Okredo data2024
Turnover (€)
1,070 €-75 % *
Sales per employee (€)
-Profit before tax (€)
759 €155 % *
Net Profit (€)
759 €155 % *
Profit per employee (€)
-Working capital requirement
3.81 394.81 % *
Debt-to-equity ratio
0.00 -100.00 % *
Total profitability (%)
81.87 %11.57 % *
Net profitability (%)
70.93 %319.33 % *
Equity (€)
4,077 €23 % *
Amounts Payable And Liabilities (€)
0 €-100 % *
Non-current Assets (€)
0 €- *
CurrentAssets (€)
4,077 €16 % *